These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2957969)

  • 1. Protective effects of a new specific thromboxane antagonist in arachidonate-induced sudden death.
    Lefer DJ; Mentley RK; Lefer AM
    Arch Int Pharmacodyn Ther; 1987 May; 287(1):89-95. PubMed ID: 2957969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective actions of a new potent thromboxane receptor antagonist in arachidonate induced sudden death.
    Liao P; Johnson G; Siegfried M; Lefer AM
    Eicosanoids; 1989; 2(1):33-7. PubMed ID: 2534470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of the protective action of Bay-u-3405, a new specific thromboxane receptor antagonist, in arachidonate-induced sudden death.
    Ma XL; Karasawa A; Lefer AM
    Methods Find Exp Clin Pharmacol; 1991 Mar; 13(2):105-10. PubMed ID: 1906568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate against 9,11-dideoxy- 9 alpha, 11 alpha-epoxymethano-prostaglandin F2 alpha-induced sudden death in guinea-pigs and rats.
    Shirakura S; Karasawa A; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1242-5. PubMed ID: 1815523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiaggregatory effects of thromboxane receptor antagonists in vivo.
    Darius H; Lefer AM
    Thromb Res; 1985 Dec; 40(5):663-75. PubMed ID: 2935972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective actions of ibuprofen in arachidonate-induced sudden death.
    Roth DM; Burke SE; Lefer AM
    Pharmacology; 1983; 27(3):169-75. PubMed ID: 6413987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective actions of a new thromboxane synthetase inhibitor in arachidonate induced sudden death.
    Edmonds LC; Lefer AM
    Life Sci; 1984 Oct; 35(17):1763-8. PubMed ID: 6434893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug.
    Stegmeier K; Pill J; Müller-Beckmann B; Schmidt FH; Witte EC; Wolff HP; Patscheke H
    Thromb Res; 1984 Aug; 35(4):379-95. PubMed ID: 6385334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the thromboxane receptor antagonist, BM 13.505, on the sequelae of endotoxemia in the conscious rat.
    Smith EF; Jugus M; Kinter LB
    Eicosanoids; 1988; 1(1):27-33. PubMed ID: 3078574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of thromboxane receptor antagonists on venous thrombosis in rats.
    Schumacher WA; Heran CL
    J Pharmacol Exp Ther; 1989 Mar; 248(3):1109-15. PubMed ID: 2522985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardioprotective actions of thromboxane receptor antagonism in ischemic atherosclerotic rabbits.
    Osborne JA; Lefer AM
    Am J Physiol; 1988 Aug; 255(2 Pt 2):H318-24. PubMed ID: 2970233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects of the thromboxane receptor antagonists BM 13.177 and BM 13.505 against U 46619-induced sudden death in rats.
    Smith EF; McDonald J
    Pharmacology; 1988; 36(5):340-7. PubMed ID: 3406046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
    Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
    Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of BAY U 3405, a new thromboxane antagonist, on arachidonic acid induced thromboembolism.
    Seuter F; Perzborn E; Fiedler VB
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():355-8. PubMed ID: 1825569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of thromboxanes and prostaglandin endoperoxides in the pathogenesis of eicosanoid induced sudden death.
    Lefer AM; Burke SE; Smith JB
    Thromb Res; 1983 Nov; 32(3):311-20. PubMed ID: 6419378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sudden death induced by intracoronary platelet aggregation.
    Yamazaki H; Isohisa I; Tanoue K
    Jpn Circ J; 1983 May; 47(5):596-607. PubMed ID: 6406715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BM 13.505, a selective thromboxane receptor antagonist, reduces myocardial infarct size following coronary artery reperfusion.
    Smith EF; Earl CQ; Egan JW
    Prostaglandins Leukot Essent Fatty Acids; 1989 Oct; 38(1):15-23. PubMed ID: 2532749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of a new potent and specific thromboxane receptor antagonist (SQ-29,548) in vitro and in vivo.
    Darius H; Smith JB; Lefer AM
    J Pharmacol Exp Ther; 1985 Nov; 235(2):274-81. PubMed ID: 2997428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.